Liver Transplant Assessment: An Evidence-Based Guide to Preparing for the Workup
f your hepatologist has told you that you may be a candidate for liver transplantation and that you will need to undergo formal assessment, you are in a clinically distinct phase of your liver disease – one where the work you do over the coming weeks and months can materially influence whether you are accepted onto the transplant waiting list, and how well you come through transplantation if you are. This page sets out what the assessment process involves, how transplant decisions are made, and – most importantly – what the published medical evidence shows you can do during this assessment window to maximise both your chance of acceptance and your eventual outcome.
It is written for adult patients in Ireland, the United Kingdom, the United States, Canada, Australia, and other English-speaking countries by a consultant hepatobiliary and pancreatic surgeon. Where claims are made, they are referenced to clinical practice guidelines from the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the International Liver Transplantation Society (ILTS), and the European Society for Clinical Nutrition and Metabolism (ESPEN). Full source list at the end.
Nothing in this article replaces the advice of your hepatology and transplant teams. The specific instructions they give you are tailored to your individual situation and should always take priority over anything you read here. Use this page as orientation and as a framework for the prehabilitation work that is genuinely in your hands during the assessment period.
If you are already on the waiting list, this article is the wrong one for you — please see our companion guide for patients on the active liver transplant waiting list. If you have just been told you may need assessment and you are reading this in the same evening, you are in the right place.
What being a ‘potential candidate’ means
A hepatologist telling you that you may be a transplant candidate is a clinical signal, not a decision. It means that your liver disease has reached a stage where transplantation is one of the realistic future options for you, and that it is now appropriate for a formal transplant centre to assess you. That assessment is a multi-week to multi-month process involving multiple specialists, scans, blood tests, and conversations. Its purpose is to determine three things: whether your liver disease genuinely meets the criteria for transplantation; whether your overall health makes you able to safely undergo and recover from a major operation; and whether the practical, psychological, and social conditions for a successful long-term outcome are in place.
Possible outcomes of the assessment are: acceptance onto the active waiting list; deferral pending specific interventions (weight loss, abstinence period completion, dental work, treatment of a previously unrecognised cardiac or pulmonary condition); a recommendation for a different pathway (live-donor transplant in some settings, alternative treatments where appropriate); or a conclusion that transplantation is not the right option, either at this point in your illness or at all. Most patients who are referred for assessment do ultimately go forward to listing, but the proportion who do not is meaningful, and the most common reasons relate to addressable factors that prehabilitation work can directly influence.
This is the central, evidence-supported reason this article matters. Unlike the waiting-list phase – where prehabilitation aims to optimise recovery from surgery – assessment-phase prehabilitation aims to influence the decision itself.
The assessment process – what to expect
The exact sequence varies by centre, but most liver transplant assessment programmes involve the following components, typically delivered as a structured workup either across several visits or in a concentrated assessment week:
• Detailed hepatology review with confirmation of your liver disease aetiology, current severity (commonly indexed by MELD or MELD-Na score), and the projected trajectory of your disease
• Imaging – typically a triple-phase CT or MRI of the abdomen, often with vascular reconstruction, to map your liver anatomy, assess for cancer, and evaluate the portal venous system
• Cardiac assessment – usually ECG, echocardiogram, and often stress testing or coronary angiography; cardiac disease is one of the commonest assessment-period findings that influences listing decisions
• Pulmonary assessment – chest x-ray and pulmonary function tests; arterial blood gases if hepatopulmonary syndrome is suspected; echocardiogram with bubble study in selected patients
• Anaesthetic review for surgical fitness, particularly in older patients or those with significant comorbidities
• Renal function review with measured GFR in selected patients
• Dental review with required clearance from your dentist
• Psychiatric / psychological assessment – universal in modern transplant programmes; not a barrier in itself but evaluates capacity to manage the demands of post-transplant life
• Social work review – practical support, accommodation logistics, financial considerations, family support adequacy
• Dietetic review – formal assessment of nutritional status, sarcopenia, and any specific dietary interventions required
• Infectious disease screening – HIV, hepatitis B, hepatitis C, tuberculosis, varicella zoster, cytomegalovirus, Epstein-Barr virus serology, and vaccination history
• Tumour assessment if your liver disease involves hepatocellular carcinoma or cholangiocarcinoma – staging imaging and confirmation that your tumour status meets the centre’s transplant criteria
• Addiction medicine review where alcohol or substance use is part of your disease history – including verification of any required abstinence period
• Transplant surgeon consultation – the surgeon who would likely perform your operation will meet you, examine you, and discuss the procedure and its risks in detail
• Final multidisciplinary team (MDT) meeting at which the assessment findings are presented and the listing decision is made
The whole assessment process typically takes between six weeks and six months from the start to the listing decision. It can be longer if specific interventions are required (e.g. an abstinence period must complete, dental work must be done, or a cardiac issue needs treating first).
How the decision is made
Liver transplant listing decisions are taken by a full multidisciplinary team – surgeons, hepatologists, anaesthetists, psychologists, social workers, transplant coordinators, and others – using established clinical criteria. They are not the decision of any single individual.
Broadly, the decision considers four domains:
First, does your liver disease genuinely justify transplantation. There must be either: a stage of cirrhotic disease where survival without transplant is materially worse than survival with it; or hepatocellular carcinoma within accepted transplant criteria; or specific other indications (acute liver failure; selected cholangiocarcinoma protocols; selected metabolic diseases; rare circumstances). MELD-Na thresholds, Milan criteria, UCSF criteria, Up-to-Seven criteria, and similar frameworks all sit within this domain.
Second, are there any absolute contraindications. These include: untreated active sepsis; active uncontrolled extrahepatic malignancy; certain advanced cardiopulmonary disease incompatible with the operation; certain rare disease-recurrence risk patterns; and active substance use disorder in some specific situations. Absolute contraindications are uncommon but make transplantation inappropriate.
Third, are there any relative contraindications that could be addressed. These are the most common reasons assessment results in deferral rather than direct listing: BMI outside the acceptable range; smoking; active alcohol use not yet meeting the required abstinence threshold; untreated dental sepsis; inadequately controlled diabetes; psychiatric instability; or social-support gaps. Most of these are addressable. The assessment window is when they get addressed.
Fourth, are the practical conditions for long-term success present. Reliable medication adherence, attending follow-up appointments, having someone who can support you through the early recovery, having safe accommodation. These are practical questions and they are taken seriously.
Patients sometimes worry that the assessment is a test they might fail. The more accurate frame is that it is a structured process to identify what – if anything – needs addressing before transplantation can safely proceed, and to share the realistic picture of what transplantation will mean for them. The MDT is on your side. They are trying to get you safely to and through a transplant if that is the right option for you.
What you can do during the assessment window
This section is the heart of this article. Below are the evidence-supported actions you can take while assessment is underway. Some directly influence the listing decision; all influence eventual transplant outcomes; all benefit your wider health regardless of the listing outcome.
1. Abstinence – alcohol and other substances
If your liver disease is alcohol-related or if there is any current alcohol use, your transplant centre will require a documented abstinence period. Historically this was a uniform six months; current practice in many centres is more nuanced, with some allowing earlier listing in patients meeting strict psychosocial criteria – but six months remains the typical default and the safest assumption.
Practical points:
• Be completely honest with your assessment team about current and past alcohol use. Honesty is not penalised; concealment that is later discovered is. Many centres routinely test ethyl glucuronide (EtG) – a urine biomarker that detects alcohol use over the prior days to weeks.
• If you find abstinence difficult, ask for addiction medicine support. Engagement with a formal alcohol service is viewed favourably by transplant MDTs because it demonstrates commitment and provides infrastructure to maintain abstinence long-term.
• Maintain abstinence from other substances unless prescribed. Recreational drug use can be a barrier to listing.
• Smoking is also relevant. While not always a binary contraindication, smoking measurably worsens transplant outcomes and many programmes require formal cessation before listing. Cessation now also improves your fitness for the operation.
2. Weight management
Body Mass Index (BMI) outside the acceptable range is one of the commonest assessment-window issues that leads to deferral. Most transplant centres set an upper BMI threshold – commonly around 35-40 – above which the operative risk and the post-transplant complication risk become unacceptable. Low BMI in the context of advanced cirrhosis is also a concern, but for different reasons (it usually reflects severe sarcopenia, not under-nutrition in the conventional sense).
Practical points if your BMI is high:
• Discuss your target with your transplant team – the exact threshold varies by centre and by individual risk profile
• Aim for gradual weight loss, not crash dieting. Rapid weight loss in cirrhotic patients can accelerate muscle loss and worsen sarcopenia – which is itself a transplant-outcome risk
• Engage with your dietitian. Calorie restriction must be combined with high protein intake (1.2-1.5 g/kg/day per ESPEN) and physical activity to preserve muscle while reducing fat
• Pharmacological weight management and bariatric surgery have specific roles in some pre-transplant pathways but require multidisciplinary decision-making
Practical points if your BMI is low or you have significant sarcopenia:
• Nutritional rebuilding is the priority – see Article 6 below on nutrition
• Sarcopenia responds to combined nutritional and resistance-exercise intervention even in advanced liver disease, and improvements during the assessment window count in your favour
3. Smoking cessation
Smoking measurably worsens transplant outcomes (wound healing, infection rates, cardiovascular events, pulmonary complications, long-term cardiovascular and respiratory disease post-transplant). Many transplant programmes require cessation before listing. Use of nicotine replacement therapy, varenicline, or bupropion is generally compatible with cirrhotic patients but should be discussed with your hepatologist for pharmacological safety.
Cotinine testing (a nicotine metabolite) is sometimes used to verify cessation, so the cessation needs to be real and not just claimed. Engagement with formal smoking cessation services – your GP can arrange this – demonstrates commitment and provides infrastructure to maintain abstinence.
4. Mental health stability
Psychiatric assessment is universal in modern transplant programmes. Pre-existing mental health diagnoses are not, on their own, contraindications to transplantation. What the assessment is looking for is evidence of psychological stability, capacity to comprehend and consent to what transplantation will involve, and capacity to manage the demands of post-transplant care.
If you have a mental health condition, the assessment-window work is to make sure it is well-controlled, that you are engaged with appropriate services, and that any necessary medication is optimised. The transplant psychiatrist or psychologist will work collaboratively with your existing mental health team where relevant. Active engagement with mental health support is viewed positively, not negatively.
If anxiety about the assessment itself is significant – which is common – speak to your hepatology team or GP about support. Untreated anxiety and depression in the assessment period make every other domain of preparation harder.
5. Demonstrating adherence
Liver transplantation is a lifelong commitment to medication, monitoring, and follow-up. The transplant MDT looks for evidence that you can sustain this commitment. The assessment window is when that evidence is generated.
Practical points:
• Take all your current medications exactly as prescribed. If you have difficulty with adherence, raise it openly with your team – they will help you find systems that work
• Attend every scheduled appointment, scan, blood test, and clinic visit. Missed appointments during assessment are noticed and counted
• Engage with the assessment workup actively. Ask questions. Read the information you are given. Bring a list of questions to consultations. Engaged patients have better outcomes and the team notices the engagement
• If you need to reschedule something, do so with as much notice as possible and reschedule promptly – don’t let things drift
6. Social support
The assessment will explicitly consider whether you have adequate practical and emotional support for the transplant journey. This is not voyeurism or judgment – it is recognition that the early post-transplant period requires a level of support most people cannot provide for themselves.
Practical points:
• Identify the people in your life who could plausibly be your primary support during transplantation and early recovery. Involve them in your assessment visits where possible. Centres often want to meet the support person
• If your situation is more isolated than you would like, work with the transplant social worker. They have seen every variation of support arrangement and can usually find a workable plan
• Make sure someone reliable knows the practical details – where you keep your medications, which hospital, what the on-call number is, who to inform of what
7. Dental health
Untreated dental infection is a significant infection risk post-transplant and is addressable now. Most centres require formal dental clearance from your dentist before listing. Get this organised early in the assessment window – finding a dentist appointment can take weeks, and necessary treatment can take longer. Delaying dental work until late in the assessment process is one of the commonest causes of avoidable listing delay.
If you do not have a regular dentist or have not been seen recently, ask your transplant coordinator for guidance – many centres can signpost dental services familiar with pre-transplant patients.
8. Vaccinations
Several important vaccines – particularly live vaccines – cannot safely be given after transplantation. The assessment window is when these gaps are identified and addressed.
Typical pre-transplant vaccination recommendations include hepatitis A and B if not immune; pneumococcal (PCV13 and PPSV23); annual influenza; MMR catch-up if non-immune; varicella if non-immune; and herpes zoster if age-appropriate. Some live vaccines require specific timing relative to potential transplant. Your transplant centre will guide on the specifics; your GP can usually deliver the vaccinations.
9. Physical conditioning
Physical conditioning during the assessment window has the dual purpose of demonstrating your fitness for surgery and rebuilding the reserves your eventual transplant operation will draw on. Detailed evidence-based exercise guidance for patients with cirrhosis is set out in our companion article for patients on the active waiting list – the same principles apply.
Briefly: walk daily (20-30 minutes at conversational pace); add light resistance work twice or three times per week for major muscle groups; practise deep breathing daily; expect to need to pace and rest more than you used to; do not push to exhaustion. If your transplant centre has a structured prehabilitation programme, engage with it during assessment and onwards.
10. Nutrition
Nutritional optimisation during the assessment window is one of the highest-yield interventions available to you. Sarcopenia (loss of muscle mass) at the point of transplant is one of the strongest independent predictors of poor outcomes; it is also responsive to intervention in the months pre-transplant.
Key targets, in line with current ESPEN and EASL nutrition guidelines, subject to your team’s specific advice:
• Protein intake 1.2-1.5 g/kg/day (substantially higher than the obsolete low-protein advice that was historically given to cirrhotic patients)
• Small frequent meals (5-6 per day) with a late-evening protein-containing snack
• Branched-chain amino acid supplementation where indicated
• Salt restriction (typically 2 g sodium / day) if ascites is present
• Absolute alcohol abstinence
• Avoid raw or undercooked shellfish; standard food-safety practice
Detailed guidance on nutrition in cirrhosis appears in our companion article. Engage actively with the dietitian if your centre offers one – most do.
What happens after the assessment decision
Three outcomes are possible:
**Acceptance onto the waiting list.** The MDT recommends listing; you are formally placed on the active waiting list; your prehabilitation work continues seamlessly. See our companion article for patients on the active waiting list for the next phase of preparation.
**Deferral pending interventions.** The MDT identifies one or more specific items that need addressing before listing – most commonly weight management, abstinence period completion, dental work, treatment of a cardiac or pulmonary issue. You are not declined; you are paused with a clear action list. Most patients deferred for addressable reasons do go on to be listed once those items are completed.
**A recommendation that transplantation is not the right path.** Less common, but it does happen. The reasons may include: progression of cancer beyond transplant criteria; cardiac or pulmonary disease too advanced for the operation; psychosocial circumstances that cannot be addressed; or a clinical judgment that transplantation would not improve outcomes for your specific situation. If this is the outcome, ask the team for a clear written explanation of the reasoning, ask whether second opinion at another centre is appropriate, and explore what other treatment options are available. A ‘no’ from one centre is not always a ‘no’ everywhere — and a clear understanding of why the answer was no is the most useful thing to take away.
In all three outcomes, the prehabilitation work you have done has not been wasted. The physical conditioning, the nutritional rebuilding, the abstinence work, the smoking cessation, the dental work, the mental health engagement – all of these benefit your wider health regardless of the listing outcome.
When to seek urgent attention – during the assessment phase
Certain symptoms need urgent medical attention regardless of where you are in the assessment process. Contact your hepatology team’s emergency line, attend your local emergency department, or call your country’s emergency services for any of the following:
• Black or tarry stools, or vomiting blood – possible variceal bleed, a medical emergency
• Confusion, disorientation, marked drowsiness, or personality change – possible hepatic encephalopathy
• Rapidly increasing abdominal swelling or new shortness of breath at rest
• Fever above 38°C, particularly with chills or shaking – possible infection, including spontaneous bacterial peritonitis if you have ascites
• New or significantly worsening jaundice
• Significant reduction in urine output
• Severe abdominal pain that is new or different from your usual pattern
• Falls, head injuries, or significant bruising – given altered coagulation in cirrhosis
Do not delay presentation while assessment is underway. Early treatment of complications keeps you eligible for transplantation and prevents avoidable deterioration.
Frequently asked questions
How long does the assessment take?
Typically six weeks to six months, depending on your centre, the complexity of your case, and whether any specific interventions are required. Centres that deliver concentrated assessment weeks can complete the core workup faster; centres that schedule visits sequentially across months take longer. Your transplant coordinator will give you a centre-specific timeline.
What is the chance I will be accepted onto the list?
This depends entirely on your individual circumstances. Most patients referred for formal assessment do go on to be listed – but the proportion who do not is meaningful and varies by centre and by disease aetiology. Ask your hepatologist directly what proportion of patients with your specific disease profile go forward to listing at your referring centre. You will get an honest answer.
What if I have been told I need to lose weight before I can be listed?
Weight loss in this context must be done carefully, because rapid weight loss in cirrhotic patients can accelerate muscle loss. Engage with your dietitian; combine modest calorie reduction with high protein intake and physical activity; aim for gradual loss; track changes; report progress to the team. Some centres support bariatric surgery in selected patients pre-transplant – if this is relevant to you, the conversation should be multidisciplinary.
What if I drank alcohol recently but my disease is not alcohol-related?
Be honest with your team. Even in non-alcohol-related liver disease, alcohol use during the assessment period is viewed unfavourably because the eventual transplant will be threatened by ongoing alcohol use. Most centres expect complete abstinence from candidacy onwards regardless of the underlying disease.
Will I have to stop my current job?
Many patients continue to work during the assessment period, particularly in less physically demanding roles. As your disease progresses, work may become harder. An honest conversation with your employer early on is usually best. Realistic time off work for a successful liver transplant is three to six months post-transplant; longer for physically demanding roles.
Can I get a second opinion?
Yes. Particularly if your assessment outcome is that transplantation is not the right pathway, a second opinion at another transplant centre may be valuable – different centres sometimes have different criteria for specific situations. Ask your hepatologist to facilitate the referral.
What about live-donor liver transplantation?
In some countries and at some centres, live-donor liver transplantation is an option. A healthy adult – usually a family member – donates a portion of their liver, which regenerates in both donor and recipient. If you have a potential live donor and your centre offers this option, the donor undergoes their own structured assessment in parallel with yours. Discuss with your team early if this is something you want to explore.
How long does a liver transplant last?
Modern liver transplant outcomes are good. Across most centres, 1-year survival after transplant is around 90%, 5-year survival around 75-80%, and many patients live decades after transplant with good quality of life. Outcomes vary by indication and individual factors. The transplant is not a cure for the underlying condition – some diseases (e.g. autoimmune hepatitis, primary sclerosing cholangitis, viral hepatitis if not properly suppressed) can recur in the new liver – but transplant offers materially better outcomes than continued chronic liver disease in most situations.
Bottom line
The assessment period for liver transplantation is the only window in your liver disease journey in which prehabilitation work can directly influence the clinical decision being made about you, as well as your eventual outcomes. The work in the assessment window is therefore especially worth doing. Engage with the workup actively; be honest with your team; address the addressable factors (weight, abstinence, smoking, dental, mental health, vaccinations); rebuild muscle through structured nutrition and conditioning; demonstrate adherence and engagement; ensure your support arrangements are clear. If you are accepted onto the list, this work continues seamlessly into your waiting-list phase. If you are deferred, you have a clear action list. If transplantation turns out not to be the right path, the work you have done has still improved your wider health and is not wasted.
Trust your transplant team. Use them. Ask them anything. And do the daily work of preparation, even when the assessment process feels long – because the work you do in this window genuinely shapes the chapter that follows.
Sources
Key references underpinning the clinical statements in this article:
• European Association for the Study of the Liver (EASL). Clinical Practice Guidelines on liver transplantation. Journal of Hepatology.
• American Association for the Study of Liver Diseases (AASLD). Practice Guidance on evaluation for liver transplantation in adults.
• International Liver Transplantation Society (ILTS). Consensus and practice guidance documents on perioperative care of the liver transplant recipient.
• European Society for Clinical Nutrition and Metabolism (ESPEN). Practical guidelines on clinical nutrition in liver disease.
• Lai JC et al. The Liver Frailty Index improves mortality prediction in patients with cirrhosis. Hepatology.
• Tandon P et al. Sarcopenia and frailty in decompensated cirrhosis. Journal of Hepatology.
• Plauth M et al. ESPEN guideline on clinical nutrition in liver disease. Clinical Nutrition.
• Burra P et al. EASL Clinical Practice Guidelines on liver transplantation.
• Asrani SK, Kamath PS. MELD and beyond: refining the prognostic assessment of cirrhosis. AASLD.
• Mathurin P et al. Early liver transplantation for severe alcoholic hepatitis. New England Journal of Medicine — for the modern abstinence-window literature.
Reviewed by Mr Tom Gallagher, Consultant Hepatobiliary & Pancreatic Surgeon, St Vincent’s Healthcare Group, Dublin. Last updated June 29th, 2026.
This article is general educational information and does not constitute medical advice. See our Disclaimer page for full terms.